

Amendments to the Claims:

The listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Canceled)
2. (Currently Amended) [The] An isolated immunostimulatory PTH-rP peptide of claim 1, wherein the isolated peptide comprises consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5 or a functional variant thereof.
3. (Canceled)
4. (Original) The peptide of claim 2 further comprising a helper epitope.
5. (Currently Amended) ~~A multi-epitope~~ An isolated immunostimulatory peptide comprising consisting of two or more PTH-rP peptides amino acid sequences selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:5.
6. (Currently Amended) The ~~multi-epitope~~ peptide of claim 5 wherein the ~~PTH-rP peptides~~ amino acid sequences are arranged in sequential, concatameric, or overlapping order.
7. (Currently Amended) The ~~multi-epitope~~ peptide of claim 5, further comprising a helper epitope.
8. (Canceled)
9. (Withdrawn) An isolated nucleic acid molecule encoding the PTH-rP peptide of claim 1 or 2.
10. (Withdrawn) An expression vector comprising the nucleic acid of claim 9.

11. (Withdrawn) A delivery vector comprising the expression vector of claim 10.
12. (Withdrawn) A virosome comprising the expression vector of 11.
13. (Withdrawn) A composition comprising a virosome encapsulating the PTH-rP peptide of claim 1.
14. (Withdrawn) A composition comprising a virosome encapsulating the PTH-rP peptide of claim 2, 5 or 8.
15. (Withdrawn) A composition comprising a virosome crosslinked to the PTH-rP peptide of claim 1.
16. (Withdrawn) A composition comprising a virosome crosslinked to the PTH-rP peptide of claim 2, 5 or 8.
17. (Withdrawn) A composition comprising a virosome encapsulating a nucleic acid comprising SEQ ID NO:9.
18. (Canceled)
19. (Original) A kit comprising the PTH-rP peptide of claim 2 and instructions for use.
20. (Withdrawn) A method of generating T cells active against PTH-rP expressing tumors and metastases comprising stimulating T cells in the presence of antigen presenting cells that have been exposed to the PTH-rP peptides of claim 1 or 2.
21. (Withdrawn) The method of claim 16, wherein the antigen presenting cells have been infected with virosomes containing PTH-rP plasmids.
22. (Withdrawn) The method of claim 16, wherein the antigen presenting cells have been infected with virosomes encapsulating the PTH-rP peptides of claim 1 or 2.

23. (Withdrawn) The method of claim 16, wherein the antigen presenting cells have been infected by virosomes with the peptides of claim 1 or 2 crosslinked to the virosome surface.

24. (Withdrawn) A method of generating a T cell response specific for PTH-rP comprising immunizing a subject with the peptides of claims 1 or 2.

25. (Withdrawn) A method of inducing an immune response against tumors or metastases expressing PTH-rP comprising immunizing a subject with the compositions of claim 1 –13.

26. (Withdrawn) A method of treating PTH-rP expressing tumors and metastases comprising administering to a subject a therapeutically effective amount of the compositions of claims 1-13.

27. (Withdrawn) A method of immunizing subject against metastases and tumors comprising administering to a subject a therapeutically effective amount of the compositions of claims 1-13.

28. (Withdrawn) A method of preventing the occurrence or recurrence of PTH-rP expressing tumors or metastases comprising administering to a subject a therapeutically effective amount of the compositions of claims 1-13.